Contact Us
Drug Search Results
More Filters [+]

Fosbretabulin

Alternative Names: fosbretabulin, combretastatin a-4 phosphate, combretastatin a4 phosphate
Latest Update: 2024-06-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Oncotelic
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fosbretabulin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Ovarian Cancer|Thyroid Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Anaplastic Thyroid Carcinoma

Phase 2: Choroid Diseases|Neuroendocrine Tumors|Choroidal Neovascularization|Myopia, Degenerative|Peritoneal Cancer|Wet Macular Degeneration|Ovarian Cancer|Oncology Solid Tumor Unspecified|Head and Neck Cancer|Anaplastic Thyroid Carcinoma|Thyroid Cancer

Phase 1: Oncology Solid Tumor Unspecified|Vascular Cancer|Neuroendocrine Tumors

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MCC-16-GI-99-PMC

P1

Terminated

Neuroendocrine Tumors

2018-06-05

PAZOFOS

P2

Terminated

Ovarian Cancer

2017-11-24

PAZOFOS

P2

Terminated

Ovarian Cancer

2017-11-21

FOCUS

P3

Terminated

Ovarian Cancer

2017-10-01

Recent News Events

Date

Type

Title

06/01/2024

PubMed

 Super-Resolution Ultrasound Imaging for Monitoring the Therapeutic Efficacy of a Vascular Disrupting Agent in an Animal Model of Breast Cancer.

01/16/2024

PubMed

 3,4-Diarylisoxazoles-Analogues of Combretastatin A-4: Design, Synthesis, and Biological Evaluation In Vitro and In Vivo.

01/01/2024

PubMed

 Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade.

09/29/2023

News Article

 Pancreatic Endocrine Tumor Drug Market 2023 Scope and Growth Prediction Outlook 2029

05/11/2022

News Article

 ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORS

01/05/2022

News Article

 Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma

05/05/2020

News Article

 FDA Grants Pediatric Disease Designation for Mateon's CA4P

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions